Brazil Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Brazil Oral Anti-Diabetic Drug Market Analysis

The Brazil Oral Anti-Diabetic Drug Market is expected to register a CAGR of more than 3% during the forecast period, with revenue of USD 13 billion in the current year.

The COVID-19 pandemic caused early fatalities during the first year of its existence, primarily in older people. The majority of COVID-19 fatalities were caused by the co-existence of two or more chronic diseases in the same person. Numerous studies have established the link between long-term conditions, including diabetes, and unfavorable outcomes in COVID-19 patients. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the makers of diabetes pharmaceuticals took special care to ensure that diabetic patients received their meds with the assistance of local governments. Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in diabetics. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. The relevance of diabetes treatment medications has been highlighted by the high incidence of diabetes among those hospitalized with COVID-19 infection and the realization that better glycemic management may improve outcomes and shorten hospital stays in COVID-19 patients.

One in ten Brazilian people, or 15.7 million individuals, or roughly 10.5% of the population, have diabetes, according to the IDF Diabetes Atlas 2021. Brazil has the third-highest global diabetes-related health expenditure, with a cost of 42.9 billion USD. Additionally, 18.9% of adults, or 18 million people, have impaired glucose tolerance, which puts them at a greater risk of becoming type 2 diabetes. In Brazil, 32% of diabetics do not have a diagnosis. Only 25% of Brazilians, according to further data on glycaemic management, achieved the treatment target of having an HbA1c of less than 7% prior to the pandemic, as advised by the Brazilian Diabetes Society (SBD).

Diabetes patients run the danger of significant and even fatal consequences like heart attack, stroke, kidney failure, blindness, and lower limb amputation when their condition is undiagnosed or not appropriately controlled. These have a negative impact on quality of life, increase healthcare spending, and make access to treatment more important. In order to combat risk factors like obesity and emerging pandemic threats, Brazil has implemented a number of reforms over the years to improve the distribution of doctors, create new types of service organizations, introduce new financing models, and implement a variety of quality improvement initiatives and policy frameworks. This also shows areas where improvements in the way diabetes treatment is provided may be expanded and continued.

Brazil Oral Anti-Diabetic Drug Market Trends

Sulfonylurea Segment Occupied the Highest Market Share in the Brazil Oral Anti-Diabetic Drugs Market in the current year.

Brazil Oral Anti-Diabetic Drug Industry Segmentation

Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in type 2 diabetes care. Brazil Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides). The report offers the value (in USD) and volume (in Units) for the above segments.